Amicus (FOLD) Price & Analysis

Compare

1,036 Followers

FOLD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.51 - $12.65

Previous CloseN/A

Volume320.41K

Average Volume (3M)4.12M

Market Cap

$2.43B

Enterprise Value$1.98B

Total Cash (Recent Filing)$231.00M

Total Debt (Recent Filing)$443.31M

Price to Earnings (P/E)―

Beta0.63

Next Earnings

Nov 05, 2025

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding308,239,380

10 Day Avg. Volume3,283,369

30 Day Avg. Volume4,122,147

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue3.46

Enterprise Value/Gross Profit3.83

Enterprise Value/Ebitda59.84

Forecast

1Y Price Target

$16.17

Price Target Upside105.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAmicus reported strong revenue growth and continued momentum in its core Pompe and Fabry disease franchises, positioning the company for GAAP profitability.

Market ExpansionSeveral additional ex-US launches are progressing, including in the Netherlands, which has the highest prevalence of Pompe disease in Europe.

Product LaunchesPombiliti+Opfolda launch is starting to gain traction with strong new patient starts across various global launches.

Bears Say

CompetitionTaking meaningful market share away from Sanofi's ERTs will remain a challenge.

Financial ChallengesFOLD reported a 2Q25 GAAP net loss of $24.4M, with an EPS of ($0.08), highlighting ongoing financial challenges.

Revenue GuidanceFY25 total revenue guidance was lowered from +17-24% at CER to +15-22% at CER due to an unexpectedly higher UK VPAG rebate rate.

Amicus News

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer

Amicus Therapeutics (($FOLD)) announced an update on their ongoing clinical study. Amicus Therapeutics is conducting a global, prospective...

22d ago

FOLD

Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer

Amicus Therapeutics (($FOLD)) announced an update on their ongoing clinical study. Amicus Therapeutics is conducting a global observational...

24d ago

FOLD

Amicus’s Strong Performance and Growth Potential Drive Buy Rating

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Amicus on July 31 and set a price...

1M ago

FOLD

Amicus price target raised to $18 from $16 at JPMorgan

JPMorgan raised the firm’s price target on Amicus (FOLD) to $18 from $16 and keeps an Overweight rating...

1M ago

FOLD

Amicus Therapeutics Reports Strong Growth Amid Strategic Advances

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

FOLD

Strong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics

Amicus, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank...

1M ago

FOLD

Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating

Maxwell Skor, an analyst from Morgan Stanley, maintained the Buy rating on Amicus. The associated price target remains...

1M ago

FOLD

Amicus Therapeutics Reports Strong Q2 2025 Growth

Amicus Therapeutics ( ($FOLD) ) has released its Q2 earnings. Here is a breakdown of the information Amicus...

1M ago

FOLD

Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Amicus, retaining the price target of $20.00....

1M ago

FOLD

Amicus Therapeutics: Strong Q2 Performance Amid Competitive Uncertainties Warrants Hold Rating

Needham analyst Gil Blum has maintained their neutral stance on FOLD stock, giving a Hold rating on July...

1M ago

FOLD

Amicus reports Q2 EPS 1c, consensus 2c

Reports Q2 revenue $154.688M, consensus $146.68M. “We delivered strong second quarter growth of 18%, marking the seventeenth consecutive...

1M ago

FOLD

Amicus sees FY25 revenue growth 15%-22%

Sees FY25 gross margin mid 80%; non-GAAP operating expenses $380M-$400M; GAAP net income positive during 2H25. Published first...

1M ago

FOLD

FOLD Earnings this Week: How Will it Perform?

Amicus Therapeutics (FOLD) is scheduled to report 2nd quarter earnings on 07/31/2025, before the market opens. Regarding Q2...

1M ago

FOLD

Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

FOLD FAQ

What was Amicus Therapeutics’s price range in the past 12 months?

Amicus Therapeutics lowest stock price was $5.51 and its highest was $12.65 in the past 12 months.

What is Amicus Therapeutics’s market cap?

Amicus Therapeutics’s market cap is $2.43B.

When is Amicus Therapeutics’s upcoming earnings report date?

Amicus Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 60 days.

How were Amicus Therapeutics’s earnings last quarter?

Amicus Therapeutics released its earnings results on Jul 31, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.038.

Is Amicus Therapeutics overvalued?

According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amicus Therapeutics pay dividends?

Amicus Therapeutics does not currently pay dividends.

What is Amicus Therapeutics’s EPS estimate?

Amicus Therapeutics’s EPS estimate is 0.04.

How many shares outstanding does Amicus Therapeutics have?

Amicus Therapeutics has 308,239,380 shares outstanding.

What happened to Amicus Therapeutics’s price movement after its last earnings report?

Amicus Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -2.284%.

Which hedge fund is a major shareholder of Amicus Therapeutics?

Currently, no hedge funds are holding shares in FOLD

Amicus Stock Smart Score

Underperform

Fundamentals

Return on Equity

-22.62%

Trailing 12-Months

Asset Growth

8.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amicus Therapeutics

Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical company focused on developing innovative therapies for rare and devastating diseases, particularly those caused by genetic mutations. The company operates primarily in the biotechnology sector, concentrating on the development of treatments for lysosomal storage disorders, including Fabry disease and Pompe disease. Amicus is known for its proprietary enzyme replacement therapies and small molecule pharmacological chaperones, which are designed to improve patient outcomes and quality of life.

Amicus (FOLD) Earnings & Revenues

Historic Earnings Reports

FOLD Company Deck

FOLD Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong quarter for Amicus Therapeutics with significant revenue growth and strategic advancements, particularly in Galafold and Pombiliti/Opfolda sales. Despite increased operating expenses and a decline in non-GAAP net income, the company's positive revenue trajectory, successful product launches, and advancements in their strategic partnership with Dimerix for DMX-200 highlight a positive outlook.View all FOLD earnings summaries

FOLD Stock 12 Month Forecast

Average Price Target

$16.17

▲(105.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,7.372307692307693,8.424615384615386,9.476923076923077,10.52923076923077,11.581538461538463,12.633846153846154,13.686153846153847,14.73846153846154,15.790769230769232,16.843076923076925,17.895384615384614,18.947692307692307,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,7.077692307692308,7.835384615384616,8.593076923076923,9.350769230769231,10.108461538461539,10.866153846153846,11.623846153846156,12.381538461538462,13.139230769230771,13.896923076923077,14.654615384615386,15.412307692307694,{"y":16.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.32,6.756923076923077,7.193846153846154,7.630769230769231,8.067692307692308,8.504615384615384,8.941538461538462,9.378461538461538,9.815384615384616,10.252307692307692,10.689230769230768,11.126153846153846,11.563076923076924,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.61,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >